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Limited data are available on the genotypic and phenotypic resistance profile of the -(1-2)mannose
oligomer-specific prokaryotic lectin cyanovirin (CV-N). Therefore, a more systematic investigation was carried
out to obtain a better view of the interaction between CV-N and human immunodeficiency virus type 1 (HIV-1)
gp120. When HIV-1-infected CEM cell cultures were exposed to CV-N in a dose-escalating manner, a total of
eight different amino acid mutations exclusively located at N-glycosylation sites in the envelope surface gp120
were observed. Six of the eight mutations resulted in the deletion of high-mannose type N-glycans (i.e., at amino
acid positions 230, 332, 339, 386, 392, and 448). Two mutations (i.e., at position 136 and 160) deleted a complex
type N-glycan in the variable V1/V2 domain of gp120. The level of phenotypic resistance of the mutated virus
strains against CV-N generally correlated with the number of glycan deletions in gp120, although deletion of
the glycans at N-230, N-392, and N-448 generally afforded a more pronounced CV-N resistance than other
N-glycan deletions. However, the extent of the decrease of antiviral activity of CV-N against the mutated virus
strains was markedly less pronounced than observed for (1-3)- and (1-6)-mannose-specific plant lectins
Hippeastrum hybrid agglutinin (HHA) and Galanthus nivalis agglutinin (GNA), which points to the existence of
a higher genetic barrier for CV-N. This is in agreement with a more consistent suppression of a wider variety
of HIV-1 clades by CV-N than by HHA and GNA. Whereas the antiviral and in vitro antiproliferative activity
of CV-N can be efficiently reversed by mannan, the pronounced mitogenic activity of CV-N on peripheral blood
mononuclear cells was unaffected by mannan, indicating that some of the observed side effects of CV-N are
unrelated to its carbohydrate specificity/activity.
Recently, carbohydrate-binding agents (CBA) received spe-
cial attention for their potential to act as anti-human immu-
nodeficiency virus (HIV) microbicides. Several plant lectins
with specificity for mannose (Man) and/or N-acetylglucos-
amine (GlcNAc) have been reported to possess favorable
properties to qualify as potential microbicidal drugs (1, 5).
Also, several CBA of prokaryotic origin or from invertebrates
have been isolated and characterized (13, 30). Among them,
cyanovirin (CV-N), an 11-kDa protein derived from the
cyanobacterium (blue-green alga) Nostoc ellipsosporum, has
received by far the most attention in this respect and has
already been thoroughly investigated on its structural prop-
erties, carbohydrate-binding potential, and associated anti-
viral activity (8–12, 22, 33). X-ray crystallographic studies of
a CV-N-Man(1,2)Man disaccharide complex and nuclear
magnetic resonance and isothermal titration calorimetry stud-
ies revealed that monomeric CV-N recognizes mannose oli-
gomers on two sides of the protein. Both sites are created by
structurally equivalent residues belonging to the two domains
of CV-N and bind primarily N-linked high-mannose oligosac-
charides, such as those found on the viral envelope of HIV type
1 (HIV-1) (11). The first binding site is less selective for the
type of mannose oligomers [i.e., Man(1,2)Man(1,2)Man,
Man(1,2)Man(1,3)Man, and Man(1,2)Man(1,6)Man
are equally recognized with similar KA values]. However, over-
all, it binds the trimannosides with higher affinities than the
second site, which shows a more pronounced discrimination
between the different trisaccharides (10). Four sugar-binding
sites can be identified in a domain-swapped dimer. It is, how-
ever, yet unclear whether CV-N exerts its antiviral activity as a
monomer or a dimer.
Very recently, the resistance profiles of the mannose-specific
plant lectins derived from Galanthus nivalis (Galanthus nivalis
agglutinin [GNA]) and Hippeastrum hybrid (Hippeastrum hy-
brid agglutinin [HHA]) have been thoroughly investigated (2,
4). Drug-escalating studies in cell culture revealed that these
CBA select for mutant HIV-1 strains that predominantly con-
tain deleted N-glycosylation sites in the envelope gp120. Such
a drug resistance profile is unprecedented in that none of the
known anti-HIV drugs, including entry inhibitors that are in
preclinical research, consistently select for such N-glycan de-
letions in gp120 (3). Consequently, the mutant virus strains do
not show measurable cross-resistance against these compounds
and vice versa; mutant HIV strains that appeared under drug
selection with DS-5000, AMD-3100, and SDF-1 did not lose
their sensitivity to be inhibited by the plant lectins irrespective
of the (nonglycan) mutations that appeared in the gp120 of the
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drug-resistant virus strains (2). The appearance of mutations at
N-glycosylation sites in HIV gp120 under drug pressure by
HHA and GNA was later confirmed to also be the case for the
mannose-binding concanavalin A and the prokaryotic lectin
CV-N (31). Very recently, a comparable mutational/resistance
spectrum was also demonstrated for the N-acetylglucosamine
(GlcNAc)-specific plant lectin derived from the stinging nettle
Urtica dioica (5).
Although N-glycans on HIV-1 gp120 were consistently deleted
under CBA pressure, a wide variety of different N-glycosylation
sites on HIV-1 gp120 (20 to 29 or even more, depending on the
particular HIV-1 strain) could be affected in CBA-exposed virus
isolates. So far only one single virus strain has been isolated under
CV-N pressure and genotypically and phenotypically character-
ized (31). Therefore, we decided to perform a more in-depth
study of the mutational pathways that could appear in the gp120
of HIV-1 strains in the presence of increasing concentrations of
CV-N to obtain more insights in the interaction of CV-N with
HIV-1 gp120. Also the cross-resistance/sensitivity spectrum of
CV-N against a wide variety of well-characterized mutant virus
strains was investigated.
MATERIALS AND METHODS
Test compounds. The mannose-specific plant lectins from Galanthus nivalis
(GNA), Hippeastrum hybrid (HHA), Listera ovata (Listera ovata agglutinin
[LOA]), and Cymbidium hybrid (Cymbidium hybrid agglutinin [CA]) were de-
rived and purified from these plants, as described before (26, 27). AMD3100 was
from AnorMed (Langley, BC, Canada), and cyanovirin (CV-N) was from J. B.
McMahon (National Institutes of Health, Bethesda, MD) and A. Bolmstedt
(Go¨teborg, Sweden).
Cells. Human T-lymphocytic CEM cells were obtained from the American
Type Culture Collection (Rockville, MD) and cultivated in RPMI 1640 medium
supplemented with 10% fetal bovine serum (BioWittaker Europe, Verviers,
Belgium), 2 mM L-glutamine, and 0.075 M NaHCO3.
Viruses. HIV-1(IIIB and BaL) was provided by R. C. Gallo and M. Popovic
(at that time at the National Cancer Institute, National Institutes of Health,
Bethesda, MD). HIV-1(HE) is a clinical isolate, derived from a Belgian AIDS
patient in 1987 and later propagated in MT-4 cells. HIV-2(ROD) was obtained
from L. Montagnier (at that time at the Pasteur Institute, Paris, France). Simian
immunodeficiency virus strain mac251 (SIVmac251) was provided by C. Bruck
(Belgium).
Antiretrovirus assays. The methodology of the anti-HIV assays has been
described previously (1). Briefly, CEM cells (4.5  105 cells per ml) were
suspended in fresh culture medium and infected with HIV-1 at 100 50% cell
culture infective doses per ml of cell suspension. Then, 100 l of the infected cell
suspension was transferred to microplate wells, mixed with 100 l of the appro-
priate dilutions of the test compounds, and further incubated at 37°C. After 4 to
5 days, giant cell formation was recorded microscopically in the CEM cell
cultures. The 50% cytostatic concentration corresponds to the compound con-
centrations required to inhibit CEM cell proliferation by 50%. The 50% effective
concentration (EC50) corresponds to the compound concentrations required to
prevent syncytium formation by 50% in the virus-infected CEM cell cultures. In
the experiments where the antiviral activity of CV-N was evaluated in the pres-
ence of mannan, 2.5 mg/ml mannan was added to the CV-N dilutions prior to the
addition of the virus-infected cell suspension.
Antiviral activity of test compounds against HIV-1 clade isolates in PBMC.
Primary clinical isolates representing different HIV-1 clades and an HIV-2 iso-
late were all kindly provided by L. Lathey from BBI Biotech Research Labora-
tories, Inc., Gaithersburg, MD, and their coreceptor use (R5 or X4) was deter-
mined by us on the astroglioma U87.CD4 cell line transfected with either CCR5
or CXCR4. The following clinical isolates were included in the study: UG273
(clade A, R5), US2 (clade B, R5), ETH2220 (clade C, R5), UG270 (clade D,
X4), ID12 (clade A/E, R5), BZ163 (clade F, R5), BCF-DIOUM (clade G, R5),
BCF06 (clade O, X4), and HIV-2 BV-5061W (X4). Antiviral testing of these
isolates in peripheral blood mononuclear cells (PBMC) was as follows. PBMC
from healthy donors were isolated by density gradient centrifugation and stim-
ulated with phytohemagglutinin (PHA) at 2 g/ml (Sigma, Bornem, Belgium) for
3 days at 37°C. The PHA-stimulated blasts were washed twice with phosphate-
buffered saline and counted by trypan blue dye exclusion. The cells were then
seeded at 0.5  106 cells per well in a 48-well plate containing various concen-
trations of compound in cell culture medium (RPMI 1640) containing 10% fetal
calf serum and interleukin-2 (25 U/ml; R&D Systems Europe, Abingdon, United
Kingdom). The virus stocks were diluted in medium and added at a final dose of
250 pg p24 or p27/ml as determined by a viral core antigen (Ag)-specific enzyme-
linked immunosorbent assay. Cell supernatant was collected at day 12, and
HIV-1 core Ag in the culture supernatant was analyzed by a p24 Ag enzyme-
linked immunosorbent assay kit (Perkin Elmer, Zaventem, Belgium). For HIV-2
p27 Ag detection, the INNOTEST from Innogenetics (Temse, Belgium) was
used.
Selection and isolation of CV-N-resistant HIV-1 strains. The procedure fol-
lowed for the selection of drug-resistant virus mutants was essentially as recently
described (4, 5). Briefly, HIV-1(IIIB or NL-4.3) was added to CEM cell cultures
in 48-well plates in the presence of 0.1 g/ml CV-N. For the generation of
drug-resistant virus mutants, an increased drug concentration was administered
when full cytopathicity was obtained in the previous cell culture. The detailed
drug resistance selection schedule is depicted in Fig. 1.
Genotyping of the HIV-1 env region. Proviral DNA was extracted from cell
pellets using the QIAamp blood mini kit (QIAGEN, Hilden, Germany). Both the
gp120 and gp41 genes were covered in this assay as recently described (29).
Effect of CV-N on [3H]thymidine incorporation. PBMC were exposed to
different concentrations of CV-N or PHA for 3 days in 96-well microtiter plates.
The experiments were performed in triplicate. Then, 0.4 Ci of [3H]thymidine
(Amersham Pharmacia, Buckinghamshire, United Kingdom) with a radiospecific
activity of 5 Ci/mmol was added to each culture. The plates were harvested 20 h
later, and [3H]thymidine incorporation into trichloroacetic acid (TCA)-insoluble
cell material, which is a measure of the mitogenic activity of the test compounds,
was measured in a scintillation counter (Canberra-Packard, Zellik, Belgium) and
expressed as disintegrations per minute. The assays were performed each time in
triplicate.
FIG. 1. Resistance selection in HIV-1(IIIB)-infected (A and B) or
HIV-1 (NL-4.3)-infected (C) CEM cell cultures in the presence of
escalating concentrations of CV-N. Every 4 to 5 days, the cell cultures
were subcultivated by adding 100 or 200 l of the virus-infected cell
suspension to 900 or 800 l fresh culture medium, respectively.
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Cytostatic/cytotoxic activity of CV-N against CEM cells and PBMC. Human
lymphocyte CEM cells were seeded at 3  105 cells/ml in culture medium in
96-well microtiter plates in the presence of serial dilutions of CV-N. After 3 to
4 days of incubation at 37°C in a CO2-controlled incubator, the cell number was
determined in a Coulter counter. The 50% inhibitory concentration was defined
as the CV-N concentration required to inhibit CEM cell proliferation by 50%.
Human PBMC were isolated, stimulated with PHA, and seeded in 48-well
plates as described above. Different concentrations of CV-N were added to the
cell cultures. Three days later, the number of living and dead cells were counted
by trypan blue dye exclusion.
Effect of CV-N on cellular activation markers in PBMC. To study the effect of
the CV-N on the expression of cellular activation markers such as CD25, CD69,
and HLA-DR antigen, PBMC were incubated with serial fivefold dilutions of
CV-N (0.9, 0.18, 0.036, and 0.007 ) or medium in the absence or presence of
PHA (2 g/ml) at 37°C. The monoclonal antibodies (MAbs) against CD4, CD8,
CD69, CD25, and HLA-DR were purchased from BD Biosciences (Erembode-
gem, Belgium).
Cell surface CD antigen expressions were analyzed at day 3 by flow cytometry.
Briefly, after washing with phosphate-buffered saline containing 2% fetal calf
serum, cells were incubated with fluorescein isothiocyanate-conjugated anti-CD8
MAb and perdinin chlorophyll protein-conjugated anti-CD4 MAb in combina-
tion with phycoerythrin-conjugated anti-CD25, -CD69, or -HLA-DR MAbs for
30 min at 4°C. As a negative control for aspecific background staining, cells were
stained in parallel with Simultest control 1/2a (BD Biosciences). Then the cells
were washed, fixed with 1% formaldehyde solution, and analyzed with a FAC-
SCalibur (BD Biosciences, San Jose, CA). Data were acquired and analyzed with
CellQuest software (BD Biosciences).
RESULTS
Antiviral activity of CV-N against HIV strains in cell cul-
ture. Cyanovirin has been evaluated for its inhibitory activity
against a broad variety of retroviral strains, including the lab-
oratory strains HIV-1 IIIB, HE, NL-4.3, and Ba-L; HIV-2
ROD and BV-5061W; SIV Mac251; and representative mem-
bers of eight different HIV-1 strains belonging to clades A, B,
C, D, A/E, F, G, and O. The strains from the D and O clades
were X4; the other clade isolates were R5 (Table 1). CV-N
showed a consistent suppression of HIV-1, HIV-2, or SIV
replication, irrespective of the nature of the virus, the cell type,
or the coreceptor tropism of the viral strain. The EC50s ranged
between 0.0007 M and 0.013 M for HIV-1(IIIB) and HIV-
2(ROD) in cell lines and between 0.013 and 0.16 M for the
variety of clinical clade isolates in PBMC. At a CV-N concen-
tration that was fivefold lower than its fully antivirally suppres-
sive concentration, very often a stimulatory effect on HIV-1
p24 production was noted for all (R5-tropic) clade isolates
(Fig. 2). However, such an effect was not observed for the
X4-tropic NL-4.3 clone. CV-N proved also markedly inhibitory
to SIV (Table 1).
Selection of CV-N-resistant HIV-1 strains. To reveal the
drug resistance profile of CV-N, three independent series of
CV-N drug resistance selections were performed using an
escalating drug selection schedule (Fig. 1). The highest possi-
ble CV-N concentration was 2 g/ml due to toxicity of the drug
at higher concentrations in the cell cultures. Selection series A
and B were performed with HIV-1(IIIB) and selection series C
with HIV-1 (NL-4.3). A total of seven virus isolates were taken
during the selection process. A long time period was required
TABLE 1. Antiviral activity of CV-N against a variety
of retroviral strains in cell culture
Viral strain(s) Cell culture type EC50 (M)
HIV-1
HE CEM 0.005
IIIB CEM 0.002
NL4.3 CEM 0.0007
PBMC 0.014
BaL M/Mb 0.16
HIV-2
ROD CEM 0.002
BV-5061W PBMC 0.033
SIV Mac251 MT-4 0.017
PBMC 0.16
HIV-1 clade isolatesa (A, B,
C, D, A/E, F, G, O)
PBMC 0.013–0.16
a The representative members of each HIV-1 clade and their X4 and/or R5
tropism have been indicated in Materials and Methods.
b M/M, monocyte/macrophage.
FIG. 2. HIV-1 p24 production in PBMC cultures that are infected by different HIV-1 strains in the presence of various CV-N concentrations.
The NL-4.3 strain is X4-tropic; the Ba-L, ETH2220, ID 12, BZ163, and UG273 strains are R5-tropic. The p24 levels in the PBMC supernatants
are expressed as percentages of p24 production in the untreated virus-infected control cultures.
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to allow the continuous presence of higher drug levels without
losing the virus upon passage of the cell cultures. In the first
HIV-1(IIIB) selection series (Fig. 1A), the virus isolate taken
at 0.1 g/ml CV-N did not show mutations in gp120, but when
taken at 1 g/ml, four mutations at N-glycosylation sites in
gp120 were observed (Table 2). In the second HIV-1(IIIB)
selection series (Fig. 1B), an isolate in the presence of 1 g/ml
CV-N contained three mutations. When two additional but
FIG. 3. Ribbon representation of the HIV-1 gp120 envelope glycoprotein (blue) bound to CD4 receptor (pink), as found in a composite of X-ray crystal
structures with Protein Data Bank identification codes 1GC1 (19, 32) and 2B4C (18). Sugar moieties are displayed as sticks, with C atoms colored white for
N-acetyl-D-glucosamine and green for fucose. The Cbeta atoms of the glycosylated N residues that are mutated in the presence of CV-N are displayed as spheres
and have been labeled. The PyMOL molecular graphics system (http://www.pymol.org; DeLano Scientific LLC, San Carlos, CA) was used for visualization and
picture creation. Clustering was done manually on the basis of proximity of the glycosylated sites. Residues 127 to 192 making up loops V1 and V2 are absent
in the crystal structures of gp120. Therefore, the approximate positions of the N-136 and N-160 residues are indicated by arrows.
TABLE 2. N-glycosylation sites in HIV-1 gp120 deleted in mutant HIV-1(IIIB or NL4.3) strains that emerged
under escalating CV-N exposurea
N-glycosylation sites
in HIV-1 gp120b
Glycan
naturec
Mutation(s) detected at CV-N concn (g/ml) (selection series, code no.)
0.1 (1, 107-10) 1 (1, 113-24) 1 (2, 108-4) 2 (2a, 113-14) 2 (2b, 113-15) 0.1 (3, 107-9) 1.5 (3, 113-23)
136NDT138 H/C 136N/K
160NIS162 H/C 162S/N 162S/N 162S/N
230NKT232 M 232T/M 232T/M
332NIS334 M 332I 334N 334N 334N
339NNT341 M 339S 339S 339S 339S 341A
386NST388 M 386D
392NST394 M 392N/T 392N/T
448NIT450 M 448N/Y 448S 448S 448S
a The wild-type virus used for the drug resistance selections was HIV-1(IIIB) for selection series 1 and 2 and HIV-1(NL4.3) for selection series 3.
b Numbering is according to the method of Kwong et al. (19). Boldface type indicates the nature of the amino acids in the glycocylation motifs.
c High-mannose type (M) versus complex/hybrid type (C/H) glycans according to Leonard et al. (21) and Gallaher et al. (16).
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independent isolates were taken late in the selection process (2
g/ml CV-N), three additional N-glycosylation site mutations
had appeared. In the third HIV-1(NL-4.3) selection series
(Fig. 1C), one mutation was found under 0.1 g/ml CV-N
exposure conditions in one of the two independent isolates.
Two mutations at N-glycosylation sites were detected in the
gp120 of the virus isolate taken in the presence of 1.5 g/ml
CV-N. Taking all virus isolates together, a total of eight CV-
N-related N-glycosylation site mutations in gp120 were found.
Six of them deleted a high-mannose type N-glycan. Two mu-
tations deleted a complex/hybrid type N-glycan according to
Leonard et al. (21) and Gallaher et al. (16) (i.e., the glycan on
positions N-136 and N-160) (Table 2). The deleted N-glycans
are plotted on the crystallographic structure of the HIV-1
gp120/CD4 complex according to Kwong et al. (19) and Huang
et al. (18) (Fig. 3).
Wild-type HIV-1-infected cell cultures that were subject to
subcultivations under similar experimental conditions did not
show any random glycan deletions at N-glycosylation sites of
gp120. These observations point to the highly specific appear-
ance of glycan deletions under CV-N drug pressure.
Phenotypic sensitivity/resistance determination of virus
strains containing N-linked glycan deletions in gp120. Seven
virus isolates were taken during the CV-N escalating selection
process, and their gp120 proteins were genotypically charac-
terized. To reveal the phenotypic sensitivity/resistance profile
of the mutant virus isolates against CV-N and other mannose-
specific lectins, five of the six isolates that contained N-glycan
deletions in the gp120 envelope were further investigated and
phenotypically characterized (Table 3).
The phenotypic resistance of CV-N against the five mutant
virus isolates ranged from 2- to 3-fold (low-level resistance) to
10- to 20-fold (high-level resistance). The virus strains with the
lowest resistance profile contained combinations of deletions
of glycans at N positions 160, 332, 339, 386, and 448. It should
be noted that the mutant amino acids at positions 160 and 448
were mixtures with their wild-type amino acids. The most pro-
nounced degree of resistance occurred when additional glycan
deletions appeared at N positions 230 (mixture with wild type)
and 392 (mixture with wild type). In these virus strains, the
glycan deletion at N-448 was invariably present as a pure
amino acid mutation, as was also the case for HIV-1 isolate
CV-N-1.0 (2), which contained the intact N-glycan at position
160 but lost the glycan at N-448. From these data, N positions
230, 392, and 448 seem to be important to provoke significant
CV-N resistance.
The HIV-1 isolates with low-level (2- to 3-fold) CV-N resis-
tance showed a 2- to 10-fold degree of resistance to the man-
nose-specific plant lectins, depending on the nature of the
lectin (GNA, HHA, LOA, CA), but kept full sensitivity to the
GlcNAc-specific Urtica dioica agglutinin (UDA) plant lectin
(Table 3). Interestingly, the MAb 2G12 completely lost its
inhibitory potential at 50 g/ml (50-fold resistance) against
these mutant virus strains. The other entry inhibitors generally
kept their antiviral potential or even became more inhibitory,
a trend that was particularly striking for T-20 and AMD3100
(Table 3). The virus isolates that showed the highest levels of
CV-N resistance (10- to 20-fold) were also 10- to 30-fold cross-
resistant to the mannose-specific plant lectins and showed
again the previously noted 50-fold resistance for 2G12. In 2
of 3 cases, T-20 still showed a threefold-more increased inhib-
itory potential than against the wild type. DS-5000 was four- to
fivefold less inhibitory than against the wild type (Table 3).
Again, the GlcNAc-specific UDA fully kept its inhibitory ac-
tivity against all high-level CV-N-resistant virus strains.
Genotypic and phenotypic properties of a broad variety of
18 HIV-1 strains with deletions of N-glycans in their gp120
envelopes. It is interesting not only to reveal the resistance/
sensitivity profile of mutant HIV-1 strains that appeared under
CV-N drug pressure but also to determine the resistance/sen-
sitivity profile of CV-N against mutant virus strains that were
selected in the presence of other CBAs. Therefore, a variety of
18 HIV-1(IIIB) strains that have been previously isolated in
drug-escalating selection experiments that were carried out in
the presence of the mannose-specific plant lectins HHA and
GNA, the GlcNAc-specific plant lectin UDA, and the low-
molecular weight mannose-specific artificial lectin pradimycin
A (PRMA) (2, 4–6) were included in the study. All of these
virus strains contained deletions in 4 to 9 N-glycans of their
gp120 envelopes. The genotypic profile and relative resistance
to CV-N and four mannose-specific plant lectins were shown in
Tables 4 and 5. Generally, those virus strains that showed the
TABLE 3. Phenotypic sensitivity of mutant virus strains to CV-N and other entry inhibitors
Entry inhibitor
EC50 (M) for:
HIV-1(IIIB)
(WT)a
HIV-1(NL-4.3)
(WT)
CV-N concn (g/ml) (selection series, code no.) (HIV-1 strain)
1 (1, 113-24)
(IIIB)
1 (2, 108-4)
(IIIB)
2 (2a, 113-14)
(IIIB)
2 (2b, 113-15)
(IIIB)
1.5 (3, 113-23)
(NL-4.3)
CV-N 0.002  0.001 0.0007 0.0005 0.005 0.003 0.016 0.003 0.040 0.021 0.039 0.023 0.005 0.0
GNA 0.005  0.001 0.011 0.009 0.017 0.01 0.140  0.030 0.116 0.120 0.076 0.064 0.018 0.028
HHA 0.004  0.002 0.013 0.004 0.020 0.005 0.130 0.015 0.068 0.018 0.042 0.017 0.056 0.036
LOA 0.003  0.001 0.014 0.003 0.071  0.028 0.031 0.0 0.030  0.026
UDA 0.138  0.041 0.053 0.004 0.213 0.056 0.287 0.172 0.115 0.0 0.218  0.016 0.138 0.056
CA 0.021  0.021 0.082  0.044 0.400 0.0 0.220  0.084 0.320 0.112 0.160 0.112
2G12b 1.1  0.12 50 50 50 50
T-20b 0.031  0.017 0.015 0.0 0.0092  0.004 0.045 0.007 0.012 0.005 0.011 0.00 0.0060  0.0028
DS 5000b 0.33  0.12 0.25  0.07 0.3  0.0 1.4  0.21 1.3  0.35 1.3  0.35 1.35  0.21
AMD3100b 0.05  0.03 0.0072  0.0011 0.021 0.016 0.070 0.028 0.06 0.0 0.065  0.007 0.014 0.006
a WT, wild type.
b Data are expressed in g/ml.
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highest resistance to CV-N (29- to 83-fold) also proved to be
the most resistant to the plant lectins (32- to 926-fold). Inter-
estingly, the virus strains that were isolated in the presence of
GNA and HHA (isolates 14 to 18) generally showed a much
more pronounced phenotypic resistance spectrum against the
plant lectin than against CV-N. It may not be a coincidence
that the N-448 glycan was invariably deleted in those virus
isolates that showed the most pronounced CV-N resistance
(i.e., isolates 18, 9, 11, 12, and 13) in addition to the N-230 and
N-392 glycan deletions (Tables 4 and 5). When we plotted the
relative resistance values obtained for CV-N against those ob-
tained for GNA, HHA, LOA, and CA, we observed no signif-
icant correlation (r range between 0.085 and 0.330) (Table 6).
However, when the relative resistance values obtained for the
different mannose-specific plant lectins were plotted against
each other, strong correlation coefficients were observed (r
range between 0.785 and 0.972).
Effect of mannan on the antiviral and cytostatic/cytotoxic
activity of cyanovirin. Since CV-N has mannose-recognizing
properties, its biological effects are expected to be influenced
in the presence of mannan. Therefore, the effect of mannan on
the CV-N properties was investigated. The antiviral activity of
CV-N against HIV-1 in CEM cell cultures was determined in
the absence or presence of 2.5 mg/ml mannan. The addition of
mannan decreased the antiviral activity of CV-N by 	20-fold
in CEM cell cultures (Fig. 4A). When the number of cells were
determined at 3 to 4 days after seeding of CEM cells or inter-
leukin-2-exposed PBMC in culture medium in the presence of
a variety of CV-N concentrations, it was found that CV-N
markedly inhibited CEM cell proliferation at relatively low
drug concentrations (50% inhibitory concentration, 0.5 to 1
M) (Fig. 4B). CV-N was also relatively toxic in PBMC cul-
tures, as determined by trypan blue staining at day 3 post
CV-N exposure (Fig. 4C). The cytostatic/cytotoxic activity of
CV-N in CEM and PBMC cultures could also be markedly
reversed in the presence of mannan (Fig. 4B,C).
Mitogenic activity of cyanovirin in PBMC cultures. Often,
lectins are endowed with mitogenic activity (i.e., PHA). There-
TABLE 4. Genotypic properties of HIV-1 strains mutated at glycosylation sites in gp120
N-glycan
position
Result for HIV-1(IIIB) isolatea:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
88 /
 /
       /
  /

136
141
156
160  
186 
197
230 /
 /
 /
  /
 /
 /
     /
  
234 /
 /
 /
 /
           
241
262
276 /
 /

289     /
    /
  /

295 /
    /
  /
  
301 /
          
332 /
        /
  
339        /
   
356
386 
392   /
    /
  
397
406   
448  /
 /
   
463
a 1, PRMA-8-1; 2, PRMA-30-1; 3, PRMA-8-2; 4, PRMA-30-2; 5, PRMA-30-3; 6, PRMA-30-4; 7, UDA-20; 8, UDA-25-1; 9, UDA-50-1; 10, UDA-15-2; 11, UDA-50-2;
12, UDA-100-2; 13, UDA-200-2; 14, GNA-2.1; 15, HHA-2.2; 16, HHA-500CS; 17, HHA-500SN; 18, GNA-500CS; /
, mixture of wild-type and mutant virus at the
indicated amino acid position; , deletion of an N-glycan at the indicated amino acid position.
TABLE 5. Antiviral activity of HIV-1 strains mutated at glycosylation sites in gp120
Compound
EC50 (M)
for wild
type
Antiviral activity (fold resistance) for virus isolatea:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
HHA 0.006 6.3 19 1.9 17 55 28 0.8 83 83 15 133 110 39 75 67 262 919 490
GNA 0.010 5.2 8.3 1.9 10 40 27 0.3 31 33 6.1 39 44 117 72 78 99 926 581
CA 0.024 10 11 8.1 6.7 27 13 1.9 42 45 32 39 32 45 85 58 140 233 133
LOA 5.8 3.8 5.0 5.5 1.3 32 33 10 102 158 80 43 16 109 228 246
CV-N 0.003 1.5 7.4 0.68 4.2 7.9 6.8 0.3 43 37 1.3 57 50 83 2.9 6.3 5.1 29 11
a 1, PRMA-8-1; 2, PRMA-30-1; 3, PRMA-8-2; 4, PRMA-30-2; 5, PRMA-30-3; 6, PRMA-30-4; 7, UDA-20; 8, UDA-25-1; 9, UDA-50-1; 10, UDA-15-2; 11, UDA-50-2;
12, UDA-100-2; 13, UDA-200-2; 14, GNA-2.1; 15, HHA-2.2; 16, HHA-500CS; 17, HHA-500SN; 18, GNA-500CS.
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fore, we wanted to investigate whether CV-N is also endowed
with mitogenic activity. PBMC cultures were exposed to
[3H]thymidine for 20 h. After this time period, the TCA-insol-
uble radiolabel was quantified in the cell cultures (Fig. 5).
Unstimulated PBMC incorporated 9,124 disintegrations per
minute, whereas the presence of 0.9 M CV-N inhibited the
incorporation but 0.18, 0.036, and 0.007 M CV-N markedly
and dose-dependently enhanced [3H]thymidine incorporation.
The dose of 0.9 M showed toxicity (Fig. 4) and thus provides
an explanation for the inhibition of the mitogenic activity by
CV-N at this concentration, whereas at 0.18 M, no toxicity
was observed. Thus, at 0.18, 0.036, and 0.007 M, CV-N had
stimulation indices (SI) of 16, 13, and 18, respectively. These
data were derived from triplicate experiments for two different
CV-N batches. In comparison, when PBMC was stimulated
with PHA at 0.2 and 0.04 M, SI of 12 and 3.1 were obtained
(Fig. 5). Such a pronouncedly increased SI was not observed
for the mannose-specific plant lectins GNA and HHA at con-
centrations up to 100 M (data not shown).
Effect of cyanovirin on the expression of cellular activation
markers in PBMC cultures. Since mitogenic activity of drugs
can result in the induction and expression of activation mark-
ers, PBMC were stained for the activation markers CD69,
CD25, and HLA-DR. It became apparent that CV-N stimu-
lated the expression of these markers in a dose-dependent
manner. Indeed, unstimulated PBMC at 3 days in cell culture
contained only 2.3% CD69 CD4 T cells, whereas in the
presence of 0.9, 0.18, 0.036, and 0.007 M CV-N, the percent-
ages of activated cells were markedly increased (Fig. 6A).
Comparable stimulatory effects were also noticed for CD25
and HLA-DR expression. Indeed, unstimulated PBMC at 3
days in culture contained 7.7% CD25 CD4 cells, whereas in
the presence of 0.9, 0.18, 0.036, and 0.007 M CV-N, this
number was substantially increased (Fig. 6B). Unstimulated
PBMC contained 5% HLA-DR CD4 cells, whereas in the
presence of 0.9, 0.018, 0.036 M CV-N, this number increased
again (Fig. 6C). In all cases, stimulation of the activation mark-
ers was less pronounced at the highest CV-N concentration
(0.9 M) than at lower concentrations, obviously due to the
masking of the stimulatory effect by the cell toxic effect at 0.9
M. A similar activation phenomenon has also been observed
on CD8 T cells. In comparison, PHA-stimulated PBMC (at
0.04 M) contained 13% CD69 CD4, 22% CD25 CD4,
and 8% HLA-DR CD4 cells. Moreover, when PHA and
CV-N were added to the cultures, a further enhancement of
the activation markers was observed. For example, exposure to
PHA solely resulted in 22% CD25 CD4 cells, but in com-
bination with CV-N at 0.9, 0.018, and 0.036 M this percentage
changed to 14%, 40%, and 35% CD25 CD4 cells, respec-
tively. Thus, CV-N as such has not only mitogenic properties
(see above), but in combination with PHA, it can even further
enhance cellular activation. These effects were not observed
FIG. 4. Effect of 2.5 mg/ml mannan on the anti-HIV-1 activity of
CV-N in CEM cell cultures (A) and on cell viability in CEM (B) and
PBMC (C) cell cultures. CPE, cytopathic effect.
TABLE 6. Paired correlations of the relative phenotypic resistance
between CV-N and mannose-specific plant lectins against a variety
of 18 HIV-1 strains containing glycan deletions in gp120
Lectin comparison r
CV-N vs GNA ...................................................................................0.100
CV-N vs HHA ...................................................................................0.111
CV-N vs LOA....................................................................................0.330
CV-N vs CA.......................................................................................0.085
GNA vs HHA....................................................................................0.972
GNA vs LOA.....................................................................................0.822
GNA vs CA........................................................................................0.882
HHA vs CA .......................................................................................0.932
LOA vs CA ........................................................................................0.785
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with the mannose-specific plant lectins HHA and GNA up to
10 M (data not shown).
DISCUSSION
Cyanovirin is the very first mannose-specific lectin that has
been isolated from a prokaryotic (Cyanobacterium) organism
and found to be endowed with a pronounced anti-HIV activity
in cell culture (13). CV-N efficiently and consistently inhibits a
wide variety of virus strains irrespective of the coreceptor us-
age (X4 or R5), the nature of the virus-infected target cell (cell
lines, PBMC, macrophages), and the nature of the clinical
virus isolate (covering a broad variety of HIV-1 clades and
HIV-2 and SIV strains). In this respect, CV-N is superior in
antiviral potency to other mannose-specific lectins, such as the
Amaryllidaceae lectins GNA and HHA. There exists also a
smaller range of variation of CV-N potency versus HHA and
GNA potency when the drug sensitivities of the different HIV
clades are considered (5). The plant lectins, however, are tet-
rameric proteins (4  12.5 kDa) with specificity for (1-3)-
mannose (GNA) or (1-3)/(1-6)-mannose (HHA) oligomers
(24, 28). It is unclear whether the superior activity of CV-N
both with regard to its antiviral potency and its antiviral vari-
ability spectrum is due to its differential mannose oligomer
specificity [man (1-2) oligomers], its relatively small size (a
dimer of 2  11 kDa), and/or a tighter binding to the gp120
glycans than HHA and GNA. However, the LOA and CA
lectins are also dimeric proteins (2  12.5 kDa) that are only
slightly bigger than CV-N but endowed with a mannose oli-
gomer specificity comparable to that of GNA and HHA. These
dimeric plant lectins also showed, like CV-N, a more consistent
suppression of the different HIV-1 clade isolates (5). The
(1-2) mannose oligomers are located at the outside area of
the high-mannose N-glycans and thus are easily reachable by
high-molecular-size drugs. Instead, the (1-3) and -(1-6)
mannose configurations are rather internally located in the
N-glycans and may be less easily reached by large-size CBAs.
Therefore, the relatively small size of CV-N together with its
(1-2) mannose oligomer specificity may be a prerequisite for
its potent and consistent antiviral suppression of a broad spec-
trum of HIV variants.
The consistent suppression of a wide variety of virus clade
isolates by CV-N is also suggestive of a relatively high genetic
barrier of CV-N. This is confirmed by our drug resistance
selection experiments. Indeed, it took a long time period be-
fore CV-N concentrations could be substantially increased in
the dose escalation selection experiments without losing the
virus in the cell cultures. Moreover, phenotypic drug resistance
determinations with the CV-N-resistant HIV-1 strains re-
vealed that, even in the concomitant presence of 4 N-glycan
deletions in gp120, CV-N still showed a pronounced inhibitory
potency. The high genetic barrier of CV-N against HIV is also
corroborated by the findings that most of the mutant HIV-1
isolates that were obtained earlier during GNA, HHA, UDA,
or PRMA resistance selections (2, 4–6) kept pronounced sen-
sitivity for CV-N. Only when more than 5 N-glycans were
deleted in the gp120 envelope of HIV-1 did CV-N lose signif-
icant antiviral potency (Tables 4 and 5).
Interestingly, HIV-1(IIIB) gp120 consists of 	24 glycosyla-
tion sites, 11 of them carrying high-mannose N-glycans and 13
bearing hybrid or complex type N-glycans according to Leon-
ard et al. (21) and Gallaher et al. (16). The high-mannose type
glycans have a core of a (1-3)/(1-6) mannose oligomer but
an (1,2) mannose oligomer periphery. The complex/hybrid
type glycans mainly lack (1,2) mannose oligomers. In this
perspective, it is striking that from all eight N-glycan deletions
observed in a total of five independent CV-N-exposed HIV-1
strains, six were high-mannose type N-glycans and only two
were hybrid/complex type N-glycans. In fact, they are part of a
cluster of six hybrid/complex mannose type N-glycans in the
V1/V2 loop of gp120. Such predominant selectivity to delete
high-mannose type glycans under CV-N drug pressure has not
been observed for the (1-3)/(1-6) mannose-specific plant
lectins (HHA and GNA) in previous drug selection studies.
Also here, high-mannose type glycans were statistically signif-
icantly more affected than complex/hybrid type glycans but not
as striking as observed for CV-N (2, 4). Mapping of the N-
glycan deletions on the three-dimensional structure of HIV-1
FIG. 5. Mitogenic activity of CV-N in PBMC. [3H]thymidine ([3H]dThd) incorporation in TCA-insoluble cell material was quantified after a
3-day incubation period of PBMC with CV-N or PHA, followed by 20 h of exposure to [3H]thymidine. dpm, disintegrations per minute.
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gp120 (18, 19, 32) revealed four clustered groups of glycan
deletions under CV-N drug pressure. They are marked as
three circles on the gp120 structure in Fig. 3 and two arrows
that locate the N-136 and N-160 glycan deletions among a
cluster of 6 complex/hybrid mannan type glycans in V1/V2
because they are not clearly resolved in the crystal structure
and, thus, their exact location in gp120 is uncertain. Interest-
ingly, each of the three N-glycan deletions that are associated
with the highest CV-N drug resistance in our studies (i.e.,
N-448, N-230, and N-339) belongs to a different clustered area
of N-glycans. The role of the N-136 and N-160 glycans, being
the only complex mannose type glycans in CV-N resistance, is
currently unclear. Interestingly, the single virus strain that was
selected in the presence of CV-N by Witvrouw et al. (31)
showed glycan deletions at N positions 332, 392, 397, 406, and
448. The deletions at 392, 397, and 406 were due to a deletion
of a 13-amino-acid stretch 394-TWFNSTWSTEGSN-406 af-
fecting 3 glycosylation sites at the same time. This virus strain
demonstrated a pronounced resistance toward the MAb 2G12
and a slight loss of susceptibility to the HIV adsorption inhib-
itor DS-5000. No loss of susceptibility was observed for the
entry inhibitors AMD3100 and enfuvirtide (T20). Three of the
N-glycan deletions observed in the mutant virus strain isolated
by Witvrouw et al. (31) were also found in several of the virus
isolates reported in our study (N-332, N-392, and N-448),
which resulted in a 140-fold phenotypic CV-N resistance (31).
Thus, our studies made it clear that HIV-1 has a variety of
mutational options to escape CV-N drug pressure. However,
there is a predominant preference for high-mannose type gly-
cans, and some of the high-mannose type N-glycans are mu-
tated much more frequently than other N-glycans. It is also
clear that deletions of N-glycans in gp120 rather than muta-
tions at other (nonglycosylated) amino acid areas in gp120 are
obligatory for the virus to become phenotypically resistant to
CV-N. This also explains the cross-resistance of CV-N-exposed
mutated virus strains to mannose-specific plant lectins but not
to other entry inhibitors, such as the adsorption inhibitor DS-
5000, the CXCR4 agonist SDF-1, or the CXCR4 antagonist
AMD3100. Also, the gp41 fusion inhibitor T20 is not nega-
tively affected by the glycan deletions in gp120.
The MAb 2G12 has also been shown to exert an (1-2)
mannose oligomer specificity (14, 23). However, whereas a
large number of N-glycan deletions are required to afford a
moderate decrease of CV-N sensitivity against the mutated
virus strains, one or two glycan deletions were already sufficient
for 2G12 to completely lose its antiviral potential. These ob-
servations demonstrate that neutralizing antibodies such as
2G12 have a low genetic barrier. This is obviously due to their
high specificity and selectivity of interaction with HIV-1 gp120.
In fact, the 2G12 epitope comprises N-glycans located at N-332
and N-339. These two sites are precisely those two glycans that
were present on the silent face of gp120 and that were deleted
in the CV-N-resistant virus strains as well (23). However, it is
clear that CV-N binds to many more areas on gp120 than does
2G12 (Fig. 2), likely including additional epitopes on gp120 for
CV-N interaction. This is in agreement with the observation
that CV-N can fully block binding of 2G12 to gp120 but not
vice versa (15, 23). Therefore, the antiviral activity of CBAs
such as CV-N should be endowed with a broad universally
neutralizing capacity against a variety of wild-type and mutant
viruses. Instead, the specific interaction of any monoclonal
antibody with its target glycoprotein can be easily compro-
mised and annihilated by only one or two well-defined amino
acid mutations in gp120.
Prokaryotic, fungal, invertebrate, and plant lectins have all
been suggested as potential microbicidal drugs (7). In fact,
CV-N is one of the very few entry inhibitors that have been
evaluated for its microbicidal action in simian human immu-
nodeficiency virus-infected female Macaca fascicularis mon-
keys through vaginal virus transmission (25). CV-N was found
to be highly protective in this in vivo study. CV-N is also
FIG. 6. Effect of CV-N on the expression of three activation mark-
ers in PBMC. (A) CD25 CD4 cell population; (B) CD69 CD4
cell population; (C) HLA-DR CD4 cell population.
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considered to be produced by commensal bacteria (i.e., Lacto-
bacillus sp.) that should colonize the female vagina, thereby
creating a microbicidal environment (17, 20). Lectins such as
CV-N and HHA have the advantage of binding tightly to the
HIV gp120 envelope, which results in a virtually irreversible
inactivation of the virus. However, due to their protein nature,
it may be expensive to produce proteins such as CV-N in large
quantities. Besides, it would be important to make a careful
choice on the nature of the lectin that should be selected as a
microbicidal drug candidate. Indeed, some lectins have been
shown to be endowed with unfavorable properties such as
human red blood cell agglutination, mitogenic stimulation of
PBMC, inflammatory activity, and cellular toxicity, etc. (for an
overview, see references 24 and 28). In our study, CV-N was
found to inhibit lymphocyte cell proliferation at relatively low
concentrations (i.e., 2 to 10 g/ml), that is, at a concentration
which is at least 1 to 2 orders of magnitude lower than that of
several plant lectins (such as HHA, GNA, and UDA) (1, 5).
Intriguingly, at concentrations that were 	5- to 10-fold lower
than those fully suppressing virus infection in PBMC cultures,
viral p24 production was rather stimulated. Such a phenome-
non was consistently seen for clinical isolates but not for NL-
4.3 (Fig. 2). Moreover, CV-N also proved mitogenic at (sub-
toxic) compound concentrations that are almost comparable
with those of PHA. This is another lectin with complex sugar
specificity that is commonly used for stimulation (activation) of
human PBMC (Fig. 5). Whereas the antiproliferative activity
of CV-N in CEM (and MT-4) cell cultures and PBMC can be
reversed by the addition of mannan, we found that the mito-
genic activity of CV-N could not be reversed by mannan (data
not shown), thus raising the possibility that the latter is inde-
pendent of the carbohydrate specificity of the lectin. Thus, our
observations indicate that CV-N exerts carbohydrate-indepen-
dent mitogenic activity at relatively low concentrations (i.e.,
0.18 M). Higher drug concentrations (i.e., starting from 	1
M and higher) may mask the mitogenic activity due to a
carbohydrate-related antiproliferative activity of the drug. The
latter effect was observed in both CEM/MT-4 and PBMC cul-
tures and confirmed for two different CV-N batches. The plant
lectins HHA, GNA, and UDA do not show significant mito-
genic nor antiproliferative activity in cell culture (28; and data
not shown). These observations indicate that the antiviral ac-
tivity of lectins can be dissected from some other biological
activities depending on the nature of the lectin. The highly
potent antiviral activity of CV-N in cell culture occurs at con-
centrations that are	50-fold lower than those necessary for its
antiproliferative and mitogenic activities. However, the appli-
cation of CV-N as a microbicidal drug will probably require
careful monitoring of the drug from a safety perspective, es-
pecially in the light of its pronounced mitogenic activity and
stimulatory effect on cellular differentiation markers.
In conclusion, CV-N was found to be a potent inhibitor of
infection of lymphocytes and macrophages by a broad variety
of virus isolates. Its resistance profile is rather unique and
differs from other nonlectin entry inhibitors in that it selects for
predominantly high-mannose type glycan deletions in the HIV
gp120 envelope. HIV can follow different mutational patterns
to escape from CV-N, although deletion of certain high-man-
nose type N-glycosylation sites is preferred. Although CV-N
has a potent antiviral activity and a high genetic barrier, it is
not devoid of potential side effects that are unrelated to its
carbohydrate binding properties. Careful monitoring of poten-
tial side effects should be required if CV-N is to be applied for
treatment of HIV-exposed/infected individuals.
ACKNOWLEDGMENTS
We are grateful to Ann Absillis, Lizette van Berckelaer, Yoeri
Schrooten, Sandra Claes, Rebecca Provinciael, and Eric Fonteyn for
excellent technical assistance and Christiane Callebaut for dedicated
editorial assistance.
The research was supported by the Geconcerteerde Onderzoeksac-
ties (GOA no. 05/19), the Flemish Foundation for Scientific Research
(no. G-0267-04), the European Commission (Rene´ Descartes Prize-
2001 HPAW-2002-90001 and EMPRO 503558 of the 6th Frame Work
Programme), and the Centers of Excellence from the K.U. Leuven
(EF/05/15).
REFERENCES
1. Balzarini, J., S. Hatse, K. Vermeire, K. Princen, S. Aquaro, C.-F Perno, E.
De Clercq, H. Egberink, G. Vanden Mooter, W. Peumans, E. Van Damme,
and D. Schols. 2004. Mannose-specific plant lectins from the Amaryllidaceae
family qualify as efficient microbicides for prevention of human immunode-
ficiency virus infection. Antimicrob. Agents Chemother. 48:3858–3870.
2. Balzarini, J., K. Van Laethem, S. Hatse, K. Vermeire, E. De Clercq, W.
Peumans, E. Van Damme, A.-M. Vandamme, A. Bolmstedt, and D. Schols.
2004. Profile of resistance of human immunodeficiency virus to mannose-
specific plant lectins. J. Virol. 78:10617–10626.
3. Balzarini, J. 2005. Targeting the glycans of gp120: a novel approach aimed
at the Achilles heel of HIV. Lancet Infect. Dis. 5:726–731.
4. Balzarini, J., K. Van Laethem, S. Hatse, M. Froeyen, E. Van Damme, W.
Peumans, E. De Clercq, and D. Schols. 2005. Marked depletion of glycosy-
lation sites in HIV-1 gp120 under selection pressure by the mannose-specific
plant lectins of Hippeastrum hybrid and Galanthus nivalis. Mol. Pharmacol.
67:1556–1565.
5. Balzarini, J., K. Van Laethem, S. Hatse, M. Froeyen, W. Peumans, E. Van
Damme, and D. Schols. 2005. Carbohydrate-binding agents cause deletions
of highly conserved glycosylation sites in HIV gp120. A new therapeutic
concept to hit the Achilles heel of HIV. J. Biol. Chem. 280:41005–41014.
6. Balzarini, J., K. Van Laethem, S. Hatse, A. Bugatti, M. Rusnati, S. Aquaro,
C.-F. Perno, Y. Igarashi, T. Oki, and D. Schols. 2006. Chemotherapy of
human immunodeficiency virus by pradimicin A: a novel therapeutic concept
for treatment of glycosylated enveloped viruses. Abstr. 19th Int. Conf.
Antivir. Res., abstr. 6.
7. Balzarini, J. Large-molecular-weight carbohydrate-binding agents as HIV
entry inhibitors targeting glycoprotein gp120. Curr. Opin. HIV AIDS, in
press.
8. Bewley, C. A., K. R. Gustafson, M. R. Boyd, D. G. Covell, A. Bax, G. M. Clore,
and A. M. Gronenborn. 1998. Solution structure of cyanovirin-N, a potent
HIV-inactivating protein. Nat. Struct. Biol. 5:571–578.
9. Bewley, C. A. 2001. Solution structure of a cyanovirin-N:Man alpha 1-2Man
alpha complex: structural basis for high-affinity carbohydrate-mediated bind-
ing to gp120. Structure 9:931–940.
10. Bewley, C. A., S. Kiyonaka, and I. Hamachi. 2002. Site-specific discrimina-
tion by cyanovirin-N for -linked trisaccharides comprising the three arms of
Man(8) and Man(9). J. Mol. Biol. 322:881–889.
11. Bolmstedt, A. J., B. R. O’Keefe, S. R. Shenoy, J. B. McMahon, and M. R.
Boyd. 2001. Cyanovirin-N defines a new class of antiviral agent targeting
N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol.
Pharmacol. 59:949–954.
12. Botos, I., B. R. O’Keefe, S. R. Shenoy, L. K. Cartner, D. M. Ratner, P. H.
Seeberger, M. R. Boyd, and A. Wlodawer. 2002. Structures of the complexes
of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccha-
rides. J. Biol. Chem. 277:34336–34342.
13. Boyd, M. R., K. R. Gustafson, J. B. McMahon, R. H. Shoemaker, B. R.
O’Keefe, T. Mori, R. J. Gulakowski, L. Wu, M. I. Rivera, C. M. Laurencot,
M. J. Currens, J. H. Cardellina II, R. W. Buckheit, Jr., P. L. Nara, L. K.
Pannell, R. C. Sowder II, and L. E. Henderson. 1997. Discovery of cyano-
virin-N, a novel human immunodeficiency virus-inactivating protein that
binds viral surface envelope glycoprotein gp120: potential applications to
microbicide development. Antimicrob. Agents Chemother. 41:1521–1530.
14. Calarese, D. A., C. N. Scanlan, M. B. Zwick, S. Deechongkit, Y. Mimura, R.
Kunert, P. Zhu, M. R. Wormald, R. L. Stanfield, K. H. Roux, J. W. Kelly,
P. M. Rudd, R. A. Dwek, H. Katinger, D. R. Buron, and I. A. Wilson. 2003.
Antibody domain exchange is an immunological solution to carbohydrate
cluster recognition. Science 300:2065–2071.
15. Dwek, R. A., T. D. Butters, F. M. Platt, and N. Zitzmann. 2002. Targetting
glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 1:65–75.
16. Gallaher, W. R., J. M. Ball, R. F. Garry, A. M. Martin-Amedee, and R. C.
8420 BALZARINI ET AL. J. VIROL.
Montelaro. 1995. A general model for the surface glycoproteins of HIV and
other retroviruses. AIDS Res. Hum. Retrovir. 11:191–202.
17. Giomarelli, B., R. Provvedi, F. Meacci, T. Maggi, D. Medaglini, G. Pozzi, T.
Mori, J. B. McMahon, R. Gardella, and M. R. Boyd. 2002. The microbicide
cyanovirin-N expressed on the surface of commensal bacterium Streptococ-
cus gordonii captures HIV-1. AIDS 16:1351–1356.
18. Huang, C. C., M. Tang, M. Y. Zhang, S. Majeed, E. Montabana, R. L.
Stanfield, D. S. Dimitrov, B. Korber, J. Sodroski, I. A. Wilson, R. Wyatt, and
P. D. Kwong. 2005. Structure of a V3-containing HIV-1 gp120 core. Science
310:1025–1028.
19. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A.
Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in
complex with the CD4 receptor and a neutralizing human antibody. Nature
393:648–659.
20. Lagenaur, L. A., X. Liu, D. A. Simpson, K. Essenmacher, C. Parker, C.-H.
Chang, D. Tsai, S. Rao, D. Hamer, T. P. Parks, P. P. Lee, and Q. Xu. 2005.
Development of vaginal lactobacilli for mucosal delivery of a topical micro-
bicide, cyanovirin-N (CV-N). Abstr. Int. Meet. Inst. Hum. Virol., abstr. S93.
21. Leonard, C. K., M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and
T. J. Gregory. 1990. Assignment of intrachain disulfide bonds and charac-
terization of potential glycosylation sites of the type 1 recombinant human
immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese
hamster ovary cells. J. Biol. Chem. 265:10373–10382.
22. Mori, T., R. H. Shoemaker, R. J. Gulakowski, B. L. Krepps, J. B. McMahon,
K. R. Gustafson, L. K. Pannell, and M. R. Boyd. 1997. Biochem. Biophys.
Res. Commun. 238:218–222.
23. Scanlan, C. N., R. Pantophlet, M. R. Wormald, S. E. Ollmann, R. Stanfield,
I. A. Wilson, H. Katinger, R. A. Dwek, P. M. Rudd, and D. R. Burton. 2002.
The broadly neutralizing anti-human immunodeficiency virus type 1 anti-
body 2G12 recognizes a cluster of alpha 132 mannose residues on the outer
face of gp120. J. Virol. 76:7306–7321.
24. Sharon, N., and H. Lis (ed.). 2003. Lectins, 2nd ed. Kluwer Academic
Publishers, Dordrecht, The Netherlands.
25. Tsai, C. C., P. Emau, Y. Jiang, M. B. Agy, R. J. Shattock, A. Schmidt, W. R.
Morton, K. R. Gustafson, and M. R. Boyd. 2004. Cyanovirin-N inhibits AIDS
virus infections in vaginal transmission models. AIDS Res. Hum. Retrovir.
20:11–18.
26. Van Damme, E. J. M., A. K. Allen, and W. J. Peumans. 1987. Leaves of the
orchid twayblade (Listera ovata) contain a mannose-specific lectin. Plant
Physiol. 85:566–569.
27. Van Damme, E. J. M., A. K. Allen, and W. J. Peumans. 1988. Related
mannose-specific lectins from different species of the family Amaryllidaceae.
Physiol. Plant 73:52–57.
28. Van Damme, E. J. M., W. J. Peumans, A. Pusztai, and S. Bardocz (ed.). 1998.
Handbook of plant lectins: properties and biomedical applications. John
Wiley & Sons, Chichester, United Kingdom.
29. Van Laethem, K., Y. Schrooten, P. Lemey, E. Van Wijngaerden, S. De Wit,
M. Van Ranst, and A.-M. Vandamme. 2005. A genotypic resistance assay for
the detection of drug resistance in the human immunodeficiency virus type 1
envelope gene. J. Virol. Methods 123:25–34.
30. Williams, D. C., Jr., J. Y. Lee, M. Cai, C. A. Bewley, and G. M. Clore. 2005.
Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free
and bound to Man3GlcNAc2: structural basis for specificity and high-affinity
binding to the core pentasaccharide from N-linked oligomannoside. J. Biol.
Chem. 280:29269–29276.
31. Witvrouw, M., V. Fikkert, A. Hantson, C. Pannecouque, B. R. O’Keefe, J.
McMahon, L. Stamatatos, E. De Clercq, and A. Bolmstedt. 2005. Resistance
of human immunodeficiency virus type 1 to the high-mannose binding agents
cyanovirin N and concanavalin A. J. Virol. 79:7777–7784.
32. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A.
Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV
gp120 envelope glycoprotein. Nature 393:705–711.
33. Yang, F., C. A. Bewley, J. M. Louis, K. R. Gustafson, M. R. Boyd, A. M.
Gronenborn, M. Clore, and A. Wlodawer. 1999. Crystal structure of cyano-
virin-N, a potent HIV-inactivating protein, shows unexpected domain swap-
ping. J. Mol. Biol. 288:403–412.
VOL. 80, 2006 HIV-1 RESISTANCE PROFILE OF CYANOVIRIN 8421
